Functional Tests of PODXL's Contributions to Tumorigenesis
The significance of this MCF-funded project lies in its prime aim to test whether inhibition of the cancer cell surface marker PODXL lessens tumorigenesis. Significance also is broad, and elevated PODXL expression recently has been associated with seven aggressive cancers. PODXL’s roles in tumorigenesis will be tested in two cancer models, epithelial breast carcinoma and acute myelogenous leukemia. Investigations may advance PODXL as a diagnostic/prognostic marker of breast and blood cancer progression; may provide new insight into how PODXL worsens cancer progression; and may lead to the design of PODXL inhibitors as new anti-cancer agents.